Navigation Links
PARI and Kamada Announce Positive Intermediate Phase I Results for,Inhaled Alpha-1 Antitrypsin

MONTEREY, Calif., May 31, 2007 /PRNewswire-FirstCall/ -- The first of two stages of the Phase I clinical trial show positive results for Kamada's Alpha-1 Antitrypsin (AAT) liquid drug candidate for inhalation delivered with PARI's eFlow electronic nebulizer for the treatment of patients suffering from AAT deficiency. Dosage levels studied resulted in good safety profiles and patient tolerability, leading the way to continued drug development of aerosolized AAT delivered with an optimized eFlow.

The study, which was approved by the European Medicines Agency, involved 24 patients who received various doses of inhaled AAT. AAT, also known as Alpha-1 Proteinase Inhibitor (API), is used for chronic replacement therapy in individuals who lack AAT and have an inherited form of panacinar emphysema.

Lack of AAT leads to various health problems including significant reduction in lung function, lung inflammation, shortness of breath, and recurrent exacerbations. This leads to emphysema, which is marked by damage to the walls of the air sacs in the lungs resulting in inefficient breathing and shortness of breath.

"In November 2006, we signed a strategic agreement with Kamada to develop inhaled AAT using our advanced aerosol delivery platform, eFlow. Today, we are pleased that this collaboration is showing good initial results and are optimistic that this partnership will benefit patients in the long term," said Dr. Martin Knoch, President of PARI Pharma GmbH. "By developing a targeted therapy that can be administered directly to the lungs, we believe this could be a substantial improvement and a great example of how the advancements in eFlow are helping to improve drug delivery to the lungs in the future."

AAT is currently used for replacement therapy in the form of weekly intravenous infusions that distribute the medication throughout the bloodstream in order to reach the lungs. An inhaled trea
'"/>




Page: 1 2 3

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
(Date:1/15/2014)... 15, 2014  Humberto C. Antunes,  Galderma  worldwide CEO, will ... Journal of Drugs in Dermatology (JDD) at ... The event is January 17-20, 2014, at the Omni Orlando Resort ... The ODAC is a distinguished event that ...
(Date:1/15/2014)... WOONSOCKET, R.I. , Jan. 15, 2014 MultiCell ... has filed a U.S. provisional patent application concerning composition ... formulations to achieve targeted tumor cell death.  ... very small noncoding double stranded RNA molecules (VSRNAs) which ...
(Date:1/15/2014)... Jan. 15, 2014 Reportlinker.com announces that ... in its catalogue: ... and Market Analysis to 2022 ... Dermatitis - India Drug Forecast and Market ...
Breaking Medicine Technology:Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5
... NEW YORK , Jan. 19 As part ... Parkinson,s disease, The Michael J. Fox Foundation for Parkinson,s Research ... to six biotech and pharmaceutical companies under its industry-exclusive ... projects pushing forward investigations of promising neuroprotective therapeutic targets for ...
... , THE WOODLANDS, ... Foundation announced today that it is changing its name to ... essence of hope that the organization aspires to provide to cancer ... enhance cancer care in local communities by removing barriers to prevention, ...
Cached Medicine Technology:Michael J. Fox Foundation Awards $2.1 Million to Drive Six Industry Teams' Pre-Clinical Development of Neuroprotective Parkinson's Therapies 2Michael J. Fox Foundation Awards $2.1 Million to Drive Six Industry Teams' Pre-Clinical Development of Neuroprotective Parkinson's Therapies 3US Oncology Foundation Becomes Life Beyond Cancer Foundation 2US Oncology Foundation Becomes Life Beyond Cancer Foundation 3
(Date:7/9/2014)... Australian researchers reveal that sudden, acute episodes of low ... as temperature, humidity, air pressure, wind direction and precipitation. ... a journal of the American College of Rheumatology (ACR), ... increases with higher wind speed or wind gusts, but ... World Health Organization (WHO) nearly everyone experiences low back ...
(Date:7/9/2014)... School of Medicine at the University of Pennsylvania in ... an $8 million grant from the National Cancer Institute ... (PDT) in patients with malignant pleural mesothelioma, a rare, ... in the lining of the lungs and is caused ... fund a clinical trial and additional studies looking at ...
(Date:7/9/2014)... that captures heretofore hidden ways that cells are regulated, ... makes breast cancer cells more likely to metastasize. , ... in part by blocking two other proteins that are ... two disease processes could have unexpected ties. , ... of Nature , points to the possibility of ...
(Date:7/9/2014)... Center paint a relatively optimistic picture of women,s chances ... spread to the chest wall or skin, but not ... regardless of size and whether they have involved lymph ... called "locally advanced" tumors, suggesting that they are a ... Locally advanced breast cancers of this and other types ...
(Date:7/9/2014)... The Miriam Hospital have found that people with ... depressed have difficulty sticking to a pulmonary rehabilitation ... women, and screening and brief treatment of depression ... study and its findings are published in print ... obstructive pulmonary disease is a common and often ...
Breaking Medicine News(10 mins):Health News:Low back pain? Don't blame the weather 2Health News:Penn mesothelioma program receives $8 million NCI grant 2Health News:Protein pushes breast cancer cells to metastasize 2Health News:Protein pushes breast cancer cells to metastasize 3Health News:Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses 2Health News:Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses 3Health News:Miriam Hospital study examines effect of depressed mood on pulmonary rehab completion 2
... Ph.D., a senior research scientist in the Department of ... Park, has been chosen to receive a 2009 Astellas ... Chemical Society, is given to individuals who have made ... their work in the chemical and related sciences. ...
... ... Carestream Health will Share Insights and Best Practices for Developing an Intelligent Portfolio ... Austin, Texas ... management solutions, will host a case study webinar discussing best practices for increasing ...
... , U.S. Rep. ... , WASHINGTON, Dec. 10 The Federal Employees Health Benefits ... American Federation of Government Employees, (AFGE) "Inside Government" radio program. The ... on Federal News Radio at www.federalnewsradio.com ...
... Speaker Nancy Pelosi issued the following statement today applauding ... Appropriations Act lifting the ban on federal funding for syringe ... bill passed the House this afternoon by a vote of ... syringe exchange could not be more clear. As Dr. Anthony ...
... Savient Pharmaceuticals, Inc. (Nasdaq: SVNT ) today announced that ... Morgan Healthcare Conference on Monday, January 11, 2010 at 2:30 p.m. ... Francis Hotel in San Francisco, CA. , Individuals can ... section of the company,s web site www.savient.com . Following ...
... may help avert drug errors, study authors suggest, , ... finds that even adults who know what medicines they ... getting in the hospital. , Forty-four percent of patients ... that was not actually prescribed. A patient who normally ...
Cached Medicine News:Health News:Planview and Carestream Health Discuss the Intelligent Portfolio on December 17 Webinar 2Health News:Planview and Carestream Health Discuss the Intelligent Portfolio on December 17 Webinar 3Health News:FEHBP Open Enrollment Period to be Discussed on Special Rebroadcast of 'Inside Government' 2Health News:Pelosi: Lifting the Ban on Federal Funding for Syringe Exchange is a Victory for Science and for Public Health 2Health News:Most Hospital Patients Don't Know What Meds They're Taking 2Health News:Most Hospital Patients Don't Know What Meds They're Taking 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: